Atrium Therapeutics launches as independent RNA therapeutics company for rare cardiomyopathies.

Atrium Therapeutics, a new publicly traded company, has been spun off from Novartis AG's acquisition of Avidity Biosciences. The company focuses on precision cardiology programs using targeted RNA delivery. Lead candidates ATR 1072 and ATR 1086 are expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively. Atrium Therapeutics begins operations with $270 million in cash and cash equivalents and is led by Kathleen Gallagher as President and CEO.